{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:18:34Z","timestamp":1787163514115,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacodynamic (PD) endpoints are essential for establishing the benefit-to-risk ratio for therapeutic interventions in children and neonates. This article discusses the selection of an appropriate measure of response, the PD endpoint, which is a critical methodological step in designing pediatric efficacy and safety studies. We provide an overview of existing guidance on the choice of PD endpoints in pediatric clinical research. We identified several considerations relevant to the selection and measurement of PD endpoints in pediatric clinical trials, including the use of biomarkers, modeling, compliance, scoring systems, and validated measurement tools. To be useful, PD endpoints in children need to be clinically relevant, responsive to both treatment and\/or disease progression, reproducible, and reliable. In most pediatric disease areas, this requires significant validation efforts. We propose a minimal set of criteria for useful PD endpoint selection and measurement. We conclude that, given the current heterogeneity of pediatric PD endpoint definitions and measurements, both across and within defined disease areas, there is an acute need for internationally agreed, validated, and condition-specific pediatric PD endpoints that consider the needs of all stakeholders, including healthcare providers, policy makers, patients, and families.<\/jats:p>","DOI":"10.1038\/pr.2018.38","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T09:20:39Z","timestamp":1524043239000},"page":"1095-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Useful pharmacodynamic endpoints in children: selection, measurement, and next steps"],"prefix":"10.1038","volume":"83","author":[{"given":"Lauren E","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashwant","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte I S","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Standing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Offringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"BFpr201838_CR1","unstructured":"Canadian Council of Academies Improving Medicines for Children - Expert Panel on Therapeutic Products for Infants, Children and Youth, 2014. \n                    http:\/\/www.scienceadvice.ca\/uploads\/eng\/assessments%20and%20publications%20and%20news%20releases\/therapeutics\/therapeutics_fullreporten.pdf\n                    \n                  ."},{"key":"BFpr201838_CR2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0140-6736(09)61803-1","volume":"374","author":"TP Klassen","year":"2009","unstructured":"Klassen TP, Hartling L, Hamm M, van der Lee JH, Ursum J, Offringa M . StaR Child Health: an initiative for RCTs in children. Lancet 2009;374:1310\u20131312.","journal-title":"Lancet"},{"key":"BFpr201838_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200342120-00001","volume":"42","author":"WA Colburn","year":"2003","unstructured":"Colburn WA, Lee JW . Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 2003;42:997\u20131022.","journal-title":"Clin Pharmacokinet"},{"key":"BFpr201838_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/clpt.2009.262","volume":"87","author":"N Holford","year":"2010","unstructured":"Holford N . Dosing in children. Clin Pharmacol Ther 2010;87:367\u2013370.","journal-title":"Clin Pharmacol Ther"},{"key":"BFpr201838_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/11319220-000000000-00000","volume":"12","author":"H Mulla","year":"2010","unstructured":"Mulla H . Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr Drugs 2010;12:223\u2013233.","journal-title":"Paediatr Drugs"},{"issue":"Suppl 3","key":"BFpr201838_CR6","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1542\/peds.2012-0055I","volume":"129","author":"K Williams","year":"2012","unstructured":"Williams K, Thomson D, Seto I et al. Standard 6: age groups for pediatric trials. Pediatrics 2012;129 (Suppl 3): S153\u2013S160.","journal-title":"Pediatrics"},{"key":"BFpr201838_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/bmm.11.96","volume":"5","author":"J Goldman","year":"2011","unstructured":"Goldman J, Becker ML, Jones B, Clements M, Leeder JS . Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark Med 2011;5:781\u2013794.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1183\/09059180.00006213","volume":"22","author":"S Gaine","year":"2013","unstructured":"Gaine S, Simonneau G . The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev 2013;22:487\u2013494.","journal-title":"Eur Respir Rev"},{"key":"BFpr201838_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/2045-8932.109931","volume":"3","author":"I Adatia","year":"2013","unstructured":"Adatia I, Haworth SG, Wegner M et al. Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee. Pulm Circ 2013;3:252\u2013266.","journal-title":"Pulm Circ"},{"key":"BFpr201838_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MOP.0000000000000135","volume":"26","author":"J Nicolarsen","year":"2014","unstructured":"Nicolarsen J, Ivy D . Progress in the diagnosis and management of pulmonary hypertension in children. Curr Opin Pediatr 2014;26:527\u2013535.","journal-title":"Curr Opin Pediatr"},{"key":"BFpr201838_CR11","unstructured":"Food and Drug Administration FDA General Pharmacology Considerations for Drugs and Biological Products. Guidance for Industry. Draft Guidance, 2014 \n                    http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm425885.pdf\n                    \n                  ."},{"key":"BFpr201838_CR12","doi-asserted-by":"publisher","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","volume":"128","author":"J Dunne","year":"2011","unstructured":"Dunne J, Rodriguez WJ, Murphy MD et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 2011;128:e1242\u2013e1249.","journal-title":"Pediatrics"},{"key":"BFpr201838_CR13","unstructured":"Food and Drug Administration Letters of Support Initiative, 2017 (cited 02 February 2018) \n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/ucm434382.htm\n                    \n                  ."},{"key":"BFpr201838_CR14","unstructured":"Food and Drug Administration Biomarkers Used as Outcomes, 2017 (cited 28 Nov 2017) \n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/BiomarkerQualificationProgram\/ucm535926.htm\n                    \n                  ."},{"key":"BFpr201838_CR15","unstructured":"Biomarkers Consortium Evidentiary Standards Working Group Framework for Defining Evidentiary Criteria for Biomarker Qualification, 2016 (cited 28 Nov 2017] \n                    https:\/\/fnih.org\/sites\/default\/files\/final\/pdf\/Evidentiary%20Criteria%20Framework%20Final%20Version%20Oct%2020%202016.pdf\n                    \n                  ."},{"key":"BFpr201838_CR16","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Guidelines on the Role of Pharmacokinetics in the Development of Medicinal Products in the Paediatric Population, 2006 \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003066.pdf\n                    \n                  ."},{"key":"BFpr201838_CR17","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate, 2007 \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003754.pdf\n                    \n                  ."},{"key":"BFpr201838_CR18","unstructured":"European Medicines Agency Paediatric Addendum to the CHMP Guideline in the Clinical Investigations of Medicinal Products for the Treatment of Pulmonary Hypertension, 2011 \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/02\/WC500122492.pdf\n                    \n                  ."},{"key":"BFpr201838_CR19","doi-asserted-by":"publisher","first-page":"E463","DOI":"10.1210\/jc.2012-3402","volume":"98","author":"A Sokalska","year":"2013","unstructured":"Sokalska A, Anderson M, Villanueva J et al. Effects of simvastatin on retinoic acid system in primary human endometrial stromal cells and in a chimeric model of human endometriosis. J Clin Endocrinol Metab 2013;98:E463\u2013E471.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpr201838_CR20","unstructured":"European Medicines Agency Paediatric Addendum to CHMP Guideline on Clinical Investigation of Medicinal Products in the Treatment of Lipid Disorders, 2012 \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/10\/WC500133180.pdf\n                    \n                  ."},{"key":"BFpr201838_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamapediatrics.2015.1640","volume":"169","author":"JM Davis","year":"2015","unstructured":"Davis JM, Turner MA . Global collaboration to develop new and existing drugs for neonates. JAMA Pediatr 2015;169:887\u2013888.","journal-title":"JAMA Pediatr"},{"key":"BFpr201838_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/pr.2016.221","volume":"81","author":"RM Ward","year":"2017","unstructured":"Ward RM, Benjamin D, Barrett JS et al. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res 2017;81:692\u2013711.","journal-title":"Pediatr Res"},{"key":"BFpr201838_CR23","unstructured":"EurekAlert US FDA Awards I-ACT for Children a Grant for Pediatric Medicines & Devices Network, 2017 (cited 28 November 2017]. \n                    https:\/\/www.eurekalert.org\/pub_releases\/2017-10\/zsms-ufa102417.php\n                    \n                  ."},{"key":"BFpr201838_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/archdischild-2016-310644","volume":"101","author":"LE Kelly","year":"2016","unstructured":"Kelly LE, Davies EH, Saint-Raymond A, Tomasi P, Offringa M . Important issues in the justification of a control treatment in paediatric drug trials. Arch Dis Child 2016;101:962\u2013967.","journal-title":"Arch Dis Child"},{"key":"BFpr201838_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/jphp.12637","volume":"69","author":"E Vermeulen","year":"2017","unstructured":"Vermeulen E, Anker JN, Della Pasqua O, Hoppu K, Lee JH . How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians. J Pharm Pharmacol 2017;69:439\u2013447.","journal-title":"J Pharm Pharmacol"},{"key":"BFpr201838_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/psp4.12083","volume":"5","author":"G Smania","year":"2016","unstructured":"Smania G, Baiardi P, Ceci A, Magni P, Cella M . Model-based assessment of alternative study designs in pediatric trials. Part I: frequentist approaches. CPT Pharmacometrics Syst Pharmacol 2016;5:305\u2013312.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFpr201838_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/psp4.12092","volume":"5","author":"G Smania","year":"2016","unstructured":"Smania G, Baiardi P, Ceci A, Cella M, Magni P . Model-based assessment of alternative study designs in pediatric trials. Part II: Bayesian approaches. CPT Pharmacometrics Syst Pharmacol 2016;5:402\u2013410.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFpr201838_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40264-016-0433-x","volume":"39","author":"OU Osokogu","year":"2016","unstructured":"Osokogu OU, Dodd C, Pacurariu A, Kaguelidou F, Weibel D, Sturkenboom MC . Drug safety monitoring in children: performance of signal detection algorithms and impact of age stratification. Drug Saf 2016;39:873\u2013881.","journal-title":"Drug Saf"},{"key":"BFpr201838_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/clpt.2009.77","volume":"86","author":"JA Wagner","year":"2009","unstructured":"Wagner JA . Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 2009;86:3\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"BFpr201838_CR30","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.2174\/1381612821666150901105337","volume":"21","author":"GL Kearns","year":"2015","unstructured":"Kearns GL, Artman M . Functional biomarkers: an approach to bridge pharmacokinetics and pharmacodynamics in pediatric clinical trials. Curr Pharm Des 2015;21:5636\u20135642.","journal-title":"Curr Pharm Des"},{"key":"BFpr201838_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1208\/s12248-013-9452-z","volume":"15","author":"JP Bai","year":"2013","unstructured":"Bai JP, Barrett JS, Burckart GJ, Meibohm B, Sachs HC, Yao L . Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. AAPS J 2013;15:447\u2013454.","journal-title":"AAPS J"},{"key":"BFpr201838_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/pr.2017.204","volume":"83","author":"LE Kelly","year":"2017","unstructured":"Kelly LE, Caswell K, Short MA, Parimi PS, Offringa M, Diacovo T . Response biomarkers in neonatal intervention studies. Pediatr Res 2017;83:425\u2013430.","journal-title":"Pediatr Res"},{"key":"BFpr201838_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/17520363.2.3.305","volume":"2","author":"S Amur","year":"2008","unstructured":"Amur S, Frueh FW, Lesko LJ, Huang S-M . Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med 2008;2:305\u2013311.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2217\/bmm.12.32","volume":"6","author":"F Lake","year":"2012","unstructured":"Lake F . Pediatric-specific biomarkers: an important but challenging field. Biomark Med 2012;6:237\u2013238.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2217\/bmm.10.106","volume":"4","author":"GL Kearns","year":"2010","unstructured":"Kearns GL . Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development. Biomark Med 2010;4:783\u2013786.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR36","unstructured":"FDA-NIH Biomarker Working Group BEST (Biomarkers, EndpointS and other Tools) Resource, 2016 (cited 27 October 2017). \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK402286\n                    \n                  ."},{"key":"BFpr201838_CR37","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Final Conclusions of the Pilot Joint EMEA\/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers, 2009 \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/10\/WC500004205.pdf\n                    \n                  ."},{"key":"BFpr201838_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-1-4939-1872-0_15","volume":"1243","author":"E Manolis","year":"2015","unstructured":"Manolis E, Koch A, Deforce D, Vamvakas S . The European Medicines Agency experience with biomarker qualification. Methods Mol Biol 2015;1243:255\u2013272.","journal-title":"Methods Mol Biol"},{"key":"BFpr201838_CR39","unstructured":"Food and Drug Administration Biomarkers Used as Outcomes, 2017 \n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/BiomarkerQualificationProgram\/ucm535926.htm\n                    \n                  ."},{"key":"BFpr201838_CR40","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.4049\/jimmunol.0900743","volume":"183","author":"I Bains","year":"2009","unstructured":"Bains I, Thiebaut R, Yates AJ, Callard R . Quantifying thymic export: combining models of naive T cell proliferation and TCR excision circle dynamics gives an explicit measure of thymic output. J Immunol 2009;183:4329\u20134336.","journal-title":"J Immunol"},{"key":"BFpr201838_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/infdis\/jir787","volume":"205","author":"J Lewis","year":"2012","unstructured":"Lewis J, Walker AS, Castro H et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis 2012;205:548\u2013556.","journal-title":"J Infect Dis"},{"key":"BFpr201838_CR42","unstructured":"Hoare R, Callard R, Standing J eds.Modelling CD4 T Cell Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy. Population Approach Group in Europe, 2016; Croatia \n                    www.page-meeting.org\/?abstract=3425\n                    \n                   Accessed July 2016."},{"key":"BFpr201838_CR43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/jcph.744","volume":"56","author":"Y Mulugeta","year":"2016","unstructured":"Mulugeta Y, Barrett JS, Nelson R et al. Exposure matching for extrapolation of efficacy in pediatric drug development. J Clin Pharmacol 2016;56:1326\u20131334.","journal-title":"J Clin Pharmacol"},{"key":"BFpr201838_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/cpt.176","volume":"98","author":"KL Brouwer","year":"2015","unstructured":"Brouwer KL, Aleksunes L, Brandys B et al. Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther 2015;98:266\u2013287.","journal-title":"Clin Pharmacol Ther"},{"key":"BFpr201838_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.addr.2014.01.002","volume":"73","author":"CI Barker","year":"2014","unstructured":"Barker CI, Germovsek E, Hoare RL, Lestner JM, Lewis J, Standing JF . Pharmacokinetic\/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Adv Drug Deliv Rev 2014;73:127\u2013139.","journal-title":"Adv Drug Deliv Rev"},{"key":"BFpr201838_CR46","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","volume":"65","author":"EI Nielsen","year":"2013","unstructured":"Nielsen EI, Friberg LE . Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2013;65:1053\u20131090.","journal-title":"Pharmacol Rev"},{"key":"BFpr201838_CR47","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/17512433.2016.1198256","volume":"9","author":"JM Brussee","year":"2016","unstructured":"Brussee JM, Calvier EA, Krekels EH et al. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev Clin Pharmacol 2016;9:1235\u20131244.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"BFpr201838_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1365-2125.1998.00792.x","volume":"46","author":"C Minto","year":"1998","unstructured":"Minto C, Schnider T . Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998;46:321\u2013333.","journal-title":"Br J Clin Pharmacol"},{"key":"BFpr201838_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1146\/annurev.pharmtox.40.1.67","volume":"40","author":"LB Sheiner","year":"2000","unstructured":"Sheiner LB, Steimer JL . Pharmacokinetic\/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000;40:67\u201395.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFpr201838_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10928-005-9002-0","volume":"33","author":"C Csajka","year":"2006","unstructured":"Csajka C, Verotta D . Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006;33:227\u2013279.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"BFpr201838_CR51","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2125.2004.02170.x","volume":"58","author":"U Wahlby","year":"2004","unstructured":"Wahlby U, Thomson AH, Milligan PA, Karlsson MO . Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol 2004;58:367\u2013377.","journal-title":"Br J Clin Pharmacol"},{"key":"BFpr201838_CR52","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/clpt.2008.52","volume":"83","author":"DE Mager","year":"2008","unstructured":"Mager DE, Jusko WJ . Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2008;83:909\u2013912.","journal-title":"Clin Pharmacol Ther"},{"key":"BFpr201838_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bcp.12287","volume":"79","author":"JS Barrett","year":"2015","unstructured":"Barrett JS . Paediatric models in motion: requirements for model-based decision support at the bedside. Br J Clin Pharmacol 2015;79:85\u201396.","journal-title":"Br J Clin Pharmacol"},{"key":"BFpr201838_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/cpt.169","volume":"98","author":"AA Vinks","year":"2015","unstructured":"Vinks AA, Emoto C, Fukuda T . Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther 2015;98:298\u2013308.","journal-title":"Clin Pharmacol Ther"},{"key":"BFpr201838_CR55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/pst.354","volume":"8","author":"K Ogungbenro","year":"2009","unstructured":"Ogungbenro K, Dokoumetzidis A, Aarons L . Application of optimal design methodologies in clinical pharmacology experiments. Pharm Stat 2009;8:239\u2013252.","journal-title":"Pharm Stat"},{"key":"BFpr201838_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MPG.0000000000001467","volume":"65","author":"JC Earp","year":"2017","unstructured":"Earp JC, Mehrotra N, Peters KE et al. Esomeprazole FDA approval in children with GERD: exposure-matching and exposure-response. J Pediatr Gastroenterol Nutr 2017;65:272\u2013277.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFpr201838_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/pst.1807","volume":"16","author":"M Gamalo\u2010Siebers","year":"2017","unstructured":"Gamalo\u2010Siebers M, Savic J, Basu C et al. Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation. Pharm Stat 2017;16:232\u2013249.","journal-title":"Pharm Stat"},{"key":"BFpr201838_CR58","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJMcibr1506573","volume":"373","author":"AT Hattersley","year":"2015","unstructured":"Hattersley AT, Thorens B . Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med 2015;373:974\u2013976.","journal-title":"N Engl J Med"},{"key":"BFpr201838_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/jcph.426","volume":"55","author":"MJ Fossler","year":"2015","unstructured":"Fossler MJ . Patient adherence: clinical pharmacology's embarrassing relative. J Clin Pharmacol 2015;55:365\u2013367.","journal-title":"J Clin Pharmacol"},{"key":"BFpr201838_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/00148581-200709050-00001","volume":"9","author":"D Matsui","year":"2007","unstructured":"Matsui D . Current issues in pediatric medication adherence. Paediatr Drugs 2007;9:283\u2013288.","journal-title":"Paediatr Drugs"},{"key":"BFpr201838_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0193945914524492","volume":"37","author":"LG Park","year":"2015","unstructured":"Park LG, Howie-Esquivel J, Dracup K . Electronic measurement of medication adherence. West J Nurs Res 2015;37:28\u201349.","journal-title":"West J Nurs Res"},{"key":"BFpr201838_CR62","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.4155\/bio.14.189","volume":"6","author":"S Tanna","year":"2014","unstructured":"Tanna S, Lawson G . Dried blood spot analysis to assess medication adherence and to inform personalization of treatment. Bioanalysis 2014;6:2825\u20132838.","journal-title":"Bioanalysis"},{"key":"BFpr201838_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13075-015-0814-z","volume":"17","author":"AF Hawwa","year":"2015","unstructured":"Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC . Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. Arthritis Res Ther 2015;17:295.","journal-title":"Arthritis Res Ther"},{"key":"BFpr201838_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bmj.319.7204.241","volume":"319","author":"K Gunning","year":"1999","unstructured":"Gunning K, Rowan K . ABC of intensive care: outcome data and scoring systems. BMJ 1999;319:241\u2013244.","journal-title":"BMJ"},{"key":"BFpr201838_CR65","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/bja\/aeh221","volume":"93","author":"LH Eberhart","year":"2004","unstructured":"Eberhart LH, Morin AM, Guber D et al. Applicability of risk scores for postoperative nausea and vomiting in adults to paediatric patients. Br J Anaesth 2004;93:386\u2013392.","journal-title":"Br J Anaesth"},{"key":"BFpr201838_CR66","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/art.23012","volume":"57","author":"LR Wedderburn","year":"2007","unstructured":"Wedderburn LR, Varsani H, Li CK et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007;57:1192\u20131201.","journal-title":"Arthritis Rheum"},{"key":"BFpr201838_CR67","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1164\/rccm.201111-2065OC","volume":"185","author":"M Loeve","year":"2012","unstructured":"Loeve M, Hop WC, de Bruijne M et al. Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2012;185:1096\u20131103.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFpr201838_CR68","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0304-3959(99)00239-0","volume":"84","author":"M van Dijk","year":"2000","unstructured":"van Dijk M, de Boer JB, Koot HM, Tibboel D, Passchier J, Duivenvoorden HJ . The reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-old infants. Pain 2000;84:367\u2013377.","journal-title":"Pain"},{"key":"BFpr201838_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00002508-199603000-00004","volume":"12","author":"B Stevens","year":"1996","unstructured":"Stevens B, Johnston C, Petryshen P, Taddio A . Premature infant pain profile: development and initial validation. Clin J Pain 1996;12:13\u201322.","journal-title":"Clin J Pain"},{"key":"BFpr201838_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1037\/h0026256","volume":"70","author":"J Cohen","year":"1968","unstructured":"Cohen J . Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213\u2013220.","journal-title":"Psychol Bull"},{"key":"BFpr201838_CR71","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/j.1365-2702.2009.02836.x","volume":"18","author":"E Ista","year":"2009","unstructured":"Ista E, de Hoog M, Tibboel D, van Dijk M . Implementation of standard sedation management in paediatric intensive care: effective and feasible? J Clin Nurs 2009;18:2511\u20132520.","journal-title":"J Clin Nurs"},{"key":"BFpr201838_CR72","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s11095-014-1315-5","volume":"31","author":"S Ueckert","year":"2014","unstructured":"Ueckert S, Plan EL, Ito K et al. Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling. Pharm Res 2014;31:2152\u20132165.","journal-title":"Pharm Res"},{"key":"BFpr201838_CR73","first-page":"141","volume":"2","author":"LP Finnegan","year":"1975","unstructured":"Finnegan LP, Connaughton JF Jr., Kron RE, Emich JP . Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141\u2013158.","journal-title":"Addict Dis"},{"key":"BFpr201838_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.PCC.0000149318.40279.1A","volume":"6","author":"E Ista","year":"2005","unstructured":"Ista E, van Dijk M, Tibboel D, de Hoog M . Assessment of sedation levels in pediatric intensive care patients can be improved by using the COMFORT \"behavior\" scale. Pediatr Crit Care Med 2005;6:58\u201363.","journal-title":"Pediatr Crit Care Med"},{"key":"BFpr201838_CR75","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1373\/clinchem.2004.042143","volume":"51","author":"M Steffes","year":"2005","unstructured":"Steffes M, Cleary P, Goldstein D et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem 2005;51:753\u2013758.","journal-title":"Clin Chem"},{"key":"BFpr201838_CR76","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(06)68341-4","volume":"367","author":"D Daneman","year":"2006","unstructured":"Daneman D . Type 1 diabetes. Lancet 2006;367:847\u2013858.","journal-title":"Lancet"},{"key":"BFpr201838_CR77","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/193229680900300306","volume":"3","author":"C Weykamp","year":"2009","unstructured":"Weykamp C, John WG, Mosca A . A review of the challenge in measuring hemoglobin A1c. J Diab Sci Technol 2009;3:439\u2013445.","journal-title":"J Diab Sci Technol"},{"key":"BFpr201838_CR78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00769-012-0907-1","volume":"17","author":"B Aslan","year":"2012","unstructured":"Aslan B, Gun-Munro J, Flynn GJ . Role of proficiency testing in monitoring of standardization of hemoglobin A1c methods. Accredit Qual Assur 2012;17:419\u2013424.","journal-title":"Accredit Qual Assur"},{"key":"BFpr201838_CR79","unstructured":"Food and Drug Administration Guidance for Industry. Bioanalytical Method Validation, 2001 \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm070107.pdf\n                    \n                  ."},{"key":"BFpr201838_CR80","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1542\/peds.2010-3381A","volume":"127","author":"J Dunne","year":"2011","unstructured":"Dunne J, Murphy D, Wharton G . The globalization of pediatric trials: should we be worried? Pediatrics 2011;127:e252\u2013e253 author reply e3-4.","journal-title":"Pediatrics"},{"key":"BFpr201838_CR81","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/prca.201000062","volume":"4","author":"WJ Savage","year":"2010","unstructured":"Savage WJ, Everett AD . Biomarkers in pediatrics: children as biomarker orphans. Proteomics Clin Appl 2010;4:915\u2013921.","journal-title":"Proteomics Clin Appl"},{"key":"BFpr201838_CR82","first-page":"643","volume":"54","author":"K Karbasy","year":"2015","unstructured":"Karbasy K, Lin DC, Stoianov A et al. Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: a CALIPER study of healthy community children. Clin Chem Lab Med 2015;54:643\u2013657.","journal-title":"Clin Chem Lab Med"},{"key":"BFpr201838_CR83","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2217\/bmm.12.29","volume":"6","author":"TK Sigdel","year":"2012","unstructured":"Sigdel TK, Gao X, Sarwal MM . Protein and peptide biomarkers in organ transplantation. Biomark Med 2012;6:259\u2013271.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR84","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/bmm.12.25","volume":"6","author":"A Smits","year":"2012","unstructured":"Smits A, De Cock RF, Cossey V, Knibbe CA, Allegaert K . Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates? Biomark Med 2012;6:283\u2013289.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR85","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2217\/bmm.12.28","volume":"6","author":"EA Buijs","year":"2012","unstructured":"Buijs EA, Zwiers AJ, Ista E, Tibboel D, de Wildt SN . Biomarkers and clinical tools in critically ill children: are we heading toward tailored drug therapy? Biomark Med 2012;6:239\u2013257.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR86","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2217\/bmm.12.27","volume":"6","author":"DM Kwiatkowski","year":"2012","unstructured":"Kwiatkowski DM, Goldstein SL, Krawczeski CD . Biomarkers of acute kidney injury in pediatric cardiac patients. Biomark Med 2012;6:273\u2013282.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR87","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2217\/bmm.14.36","volume":"8","author":"SJ McWilliam","year":"2014","unstructured":"McWilliam SJ, Antoine DJ, Sabbisetti V et al. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med 2014;8:1189\u20131197.","journal-title":"Biomark Med"},{"key":"BFpr201838_CR88","doi-asserted-by":"publisher","first-page":"e43809","DOI":"10.1371\/journal.pone.0043809","volume":"7","author":"SJ McWilliam","year":"2012","unstructured":"McWilliam SJ, Antoine DJ, Sabbisetti V et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS ONE 2012;7:e43809.","journal-title":"PLoS ONE"},{"key":"BFpr201838_CR89","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00467-013-2453-4","volume":"28","author":"H Schiffl","year":"2013","unstructured":"Schiffl H, Lang SM . Urinary biomarkers and acute kidney injury in children: the long road to clinical application. Pediatr Nephrology 2013;28:837\u2013842.","journal-title":"Pediatr Nephrology"},{"key":"BFpr201838_CR90","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5014\/ajot.2013.006015","volume":"67","author":"WJ Coster","year":"2013","unstructured":"Coster WJ . Making the best match: selecting outcome measures for clinical trials and outcome studies. Am J Occup Ther 2013;67:162\u2013170.","journal-title":"Am J Occup Ther"},{"key":"BFpr201838_CR91","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511996214","volume-title":"Measurement in Medicine: a Practical Guide","author":"HC De Vet","year":"2011","unstructured":"De Vet HC, Terwee CB, Mokkink LB, Knol DL . Measurement in Medicine: a Practical Guide. Cambridge University Press, 2011."},{"issue":"Suppl 3","key":"BFpr201838_CR92","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1542\/peds.2012-0055H","volume":"129","author":"IP Sinha","year":"2012","unstructured":"Sinha IP, Altman DG, Beresford MW et al. Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. Pediatrics 2012;129 (Suppl 3): S146\u2013S152.","journal-title":"Pediatrics"},{"key":"BFpr201838_CR93","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1745-6215-13-132","volume":"13","author":"PR Williamson","year":"2012","unstructured":"Williamson PR, Altman DG, Blazeby JM et al. Developing core outcome sets for clinical trials: issues to consider. Trials 2012;13:132.","journal-title":"Trials"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pr201838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr201838","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pr.2018.38","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pr201838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:05:15Z","timestamp":1684602315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pr201838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["BFpr201838"],"URL":"https:\/\/doi.org\/10.1038\/pr.2018.38","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"22 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}